Man Group plc acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 170,907 shares of the biopharmaceutical company's stock, valued at approximately $51,448,000. Man Group plc owned 0.13% of Alnylam Pharmaceuticals at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. MV Capital Management Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $25,000. HM Payson & Co. bought a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $27,000. Golden State Wealth Management LLC raised its holdings in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 36 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. Finally, Manchester Capital Management LLC lifted its position in Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 72 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on ALNY shares. JPMorgan Chase & Co. decreased their target price on Alnylam Pharmaceuticals from $400.00 to $375.00 and set an "overweight" rating on the stock in a research report on Friday, July 31st. Royal Bank Of Canada dropped their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an "outperform" rating for the company in a report on Friday, July 31st. Wall Street Zen cut Alnylam Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 2nd. Sanford C. Bernstein restated an "outperform" rating and issued a $376.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday. Finally, BMO Capital Markets began coverage on Alnylam Pharmaceuticals in a report on Wednesday, August 19th. They issued an "outperform" rating and a $318.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $386.14.
View Our Latest Analysis on Alnylam Pharmaceuticals
Alnylam Pharmaceuticals Trading Down 0.4%
Shares of NASDAQ:ALNY opened at $239.00 on Thursday. The business's 50 day simple moving average is $264.27 and its 200 day simple moving average is $294.77. Alnylam Pharmaceuticals, Inc. has a 1 year low of $197.81 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. The company has a market capitalization of $31.98 billion, a P/E ratio of 44.42 and a beta of 0.30.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to analysts' expectations of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company's quarterly revenue was up 66.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.51) EPS. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.
Insider Buying and Selling
In related news, Director David E. I. Pyott sold 3,830 shares of the business's stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares of the company's stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.
Alnylam Pharmaceuticals Company Profile
(
Free Report)
Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Further Reading
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Alnylam Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.
While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
